Inhibikase Therapeutics (IKT) Competitors $1.86 +0.06 (+3.33%) Closing price 04:00 PM EasternExtended Trading$1.86 0.00 (0.00%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKT vs. AMLX, TBPH, ATAI, KROS, TLRY, MNMD, ORGO, ZVRA, TYRA, and TSHAShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Amylyx Pharmaceuticals (AMLX), Theravance Biopharma (TBPH), atai Life Sciences (ATAI), Keros Therapeutics (KROS), Tilray Brands (TLRY), Mind Medicine (MindMed) (MNMD), Organogenesis (ORGO), Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors Amylyx Pharmaceuticals Theravance Biopharma atai Life Sciences Keros Therapeutics Tilray Brands Mind Medicine (MindMed) Organogenesis Zevra Therapeutics Tyra Biosciences Taysha Gene Therapies Amylyx Pharmaceuticals (NASDAQ:AMLX) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Do insiders & institutionals have more ownership in AMLX or IKT? 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend AMLX or IKT? Amylyx Pharmaceuticals currently has a consensus target price of $11.75, suggesting a potential upside of 39.38%. Inhibikase Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 249.46%. Given Inhibikase Therapeutics' higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, AMLX or IKT? Amylyx Pharmaceuticals has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Does the media refer more to AMLX or IKT? In the previous week, Amylyx Pharmaceuticals had 10 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 10 mentions for Amylyx Pharmaceuticals and 0 mentions for Inhibikase Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.77 beat Inhibikase Therapeutics' score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Amylyx Pharmaceuticals Positive Inhibikase Therapeutics Neutral Which has better valuation & earnings, AMLX or IKT? Inhibikase Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M8.60-$301.74M-$3.11-2.71Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.70 Is AMLX or IKT more profitable? Amylyx Pharmaceuticals' return on equity of -77.21% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -77.21% -63.84% Inhibikase Therapeutics N/A -350.63%-201.82% SummaryAmylyx Pharmaceuticals beats Inhibikase Therapeutics on 10 of the 15 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$133.82M$270.30M$5.57B$20.65BDividend YieldN/AN/A4.23%3.65%P/E Ratio-0.70N/A28.6127.29Price / SalesN/A431.06412.0053.17Price / CashN/A22.4436.0222.28Price / Book1.049.708.234.60Net Income-$19.03M-$110.10M$3.23B$995.22M7 Day Performance-7.92%-0.83%-0.01%-0.80%1 Month Performance-4.12%11.85%5.61%3.55%1 Year Performance20.78%16.17%26.52%7.35% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics1.2013 of 5 stars$1.86+3.3%$6.50+249.5%+20.8%$133.82MN/A-0.706AMLXAmylyx Pharmaceuticals3.387 of 5 stars$6.76+7.3%$11.00+62.7%+275.9%$561.59M-$1.27M-2.17200TBPHTheravance Biopharma1.7729 of 5 stars$11.31+1.4%$16.60+46.8%+16.8%$557.52M$64.38M-9.58110News CoverageInsider TradeATAIatai Life Sciences3.1692 of 5 stars$2.75-0.7%$9.00+227.3%+64.6%$554.93M$310K-3.0280Gap UpHigh Trading VolumeKROSKeros Therapeutics2.082 of 5 stars$13.40-0.4%$30.56+128.0%-72.1%$546.28M$3.55M-74.44100TLRYTilray Brands1.8648 of 5 stars$0.50-6.6%$1.92+280.7%-68.9%$542.20M$788.94M-0.482,650MNMDMind Medicine (MindMed)2.1957 of 5 stars$7.20+0.4%$25.50+254.2%+3.2%$541.72MN/A-5.5840ORGOOrganogenesis4.4654 of 5 stars$4.25flat$6.00+41.2%+39.4%$539.13M$482.04M-25.00950News CoverageAnalyst ForecastZVRAZevra Therapeutics3.0526 of 5 stars$11.27+15.7%$23.14+105.3%+105.3%$532.58M$23.61M-5.9320Trending NewsAnalyst RevisionHigh Trading VolumeTYRATyra Biosciences3.1012 of 5 stars$9.61-3.9%$30.83+220.8%-49.5%$530.90MN/A-5.9020TSHATaysha Gene Therapies3.9769 of 5 stars$2.34-4.5%$8.20+250.4%+2.9%$525.92M$8.33M-6.88180News Coverage Related Companies and Tools Related Companies AMLX Alternatives TBPH Alternatives ATAI Alternatives KROS Alternatives TLRY Alternatives MNMD Alternatives ORGO Alternatives ZVRA Alternatives TYRA Alternatives TSHA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts